^
Association details:
| Biomarker: | CEACAM5 expression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
Excerpt:
...- Expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) will be assessed centrally using the most recent archival tumor tissue (or, if...
Trial ID:
Source:
Title:
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
Excerpt:
...- Participants with moderate or negative CEACAM5 expression as demonstrated prospectively by central laboratory via immune histochemistry (ICH) and high circulating CEA levels (≥100 ng/mL)....
Trial ID:
More C2 evidence
Source:
Title:
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
Excerpt:
...Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy....
Trial ID:
Source:
Title:
SAR408701 in combination with pembrolizumab and pembrolizumab alone in patients with non-squamous non-small cell lung cancer (NSQ NSCLC) A pembrolizumabbal kombinált SAR408701 és a pembrolizumab monoterápia összehasonlítása nem laphámsejtes, nem kissejtes tüdődaganatban szenvedő betegeknél (NSQ NSCLC)
Excerpt:
...-A CEACAM5 expressziója, amelyet prospektív módon bemutattak egy ≥2 + intenzitású, központilag értékelt IHC-teszttel, a tumorsejtpopuláció legalább 50%-ánál az archív tumormintában (vagy ha ez nem áll rendelkezésre, akkor friss biopsziás mintán). ...
Trial ID:
Source:
Title:
Tusamitamab ravtansine in NSQ NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEA
Excerpt:
...- Histologically or cytologically proven diagnosis of NSQ NSCLC metastatic disease at study entry; progression after platinum-based chemotherapy and immune checkpoint inhibitor.- Participants with moderate or negative CEACAM5 expression as demonstrated prospectively by central laboratory via immune histochemistry (ICH) and high circulating CEA levels (≥100 ng/mL). ...
Trial ID:
Less C2 evidence
Source:
Title:
Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
Published date:
05/26/2022
Excerpt:
92 pts with heavily pretreated NSQ NSCLC and high (n = 64) or moderate (n = 28) CEACAM5 expression (≥ 2+ intensity in ≥ 50% of tumor cells or in ≥ 1% to < 50% of tumor cells, respectively) were treated with tusa...Of pts treated for ≥ 12 mo, PR occurred irrespective of CEACAM5 expression level….Almost half (47%) of pts who achieved a PR were treated for ≥ 1 y, suggesting that response to tusa in heavily pretreated pts was durable and frequently sustained.
DOI:
10.1200/JCO.2022.40.16_suppl.9039
Trial ID:
